2.94 USD
-0.19
6.07%
At close Feb 21, 4:00 PM EST
After hours
3.03
+0.09
3.06%
1 day
-6.07%
5 days
6.52%
1 month
1.38%
3 months
-14.53%
6 months
-37.97%
Year to date
2.80%
1 year
-4.55%
5 years
-69.31%
10 years
-20.33%
 

About: PaySign Inc is a provider of prepaid card programs, comprehensive patient affordability offerings, digital banking services, and integrated payment processing designed for businesses, consumers, and government institutions. The Company creates customized, payment solutions for clients across industries, including pharmaceutical, healthcare, hospitality, and retail. The company's revenues include fees generated from cardholder fees, interchange, card program management fees, transaction claims processing fees, and settlement income.

Employees: 123

0
Funds holding %
of 7,139 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

457% more call options, than puts

Call options by funds: $245K | Put options by funds: $44K

124% more repeat investments, than reductions

Existing positions increased: 38 | Existing positions reduced: 17

37% more capital invested

Capital invested by funds: $42.2M [Q3] → $57.7M (+$15.5M) [Q4]

14.04% more ownership

Funds ownership: 21.65% [Q3] → 35.7% (+14.04%) [Q4]

13% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 15

0% more funds holding

Funds holding: 90 [Q3] → 90 (+0) [Q4]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target
$6
104%
upside
Avg. target
$6
104%
upside
High target
$6
104%
upside

1 analyst rating

positive
100%
neutral
0%
negative
0%
Lake Street
104%upside
$6
Buy
Initiated
20 Dec 2024

Financial journalist opinion

Positive
Seeking Alpha
3 days ago
Paysign: Shifting Revenue Mix, Falling Stock, Compelling Opportunity
Paysign, Inc. is a small healthcare-focused Fintech company excelling in the $500M Patient Affordability market, with 230% revenue growth in its Pharma segment over the past four quarters. Despite a 40% stock decline in six months, Paysign's strong fundamentals and innovative solutions present a compelling investment opportunity with a fair value estimate of $3.33 per share. Paysign's strategic focus on Plasma and Patient Affordability programs, vertical integration, and innovation has driven significant growth and improved margins, funded entirely through organic cash flow.
Paysign: Shifting Revenue Mix, Falling Stock, Compelling Opportunity
Neutral
Business Wire
2 weeks ago
Paysign Announces 2024 Performance Analysis of Patient Affordability Solutions
HENDERSON, Nev.--(BUSINESS WIRE)--Paysign Announces 2024 Performance Analysis of Patient Affordability Solutions.
Paysign Announces 2024 Performance Analysis of Patient Affordability Solutions
Positive
Seeking Alpha
3 months ago
Paysign Is A Leader In Fintech Healthcare Payments With Durable Profitable Growth
Paysign is a promising microcap payment processing company with a projected 42% annualized return, potentially reaching $19/share by 2030 from $3.30/share today. The company excels in two primary sectors: plasma payment processing and pharma patient affordability, both offering significant growth and high gross margins. PAYS's plasma business boasts a 40% market share with steady 10-15% annual growth, while the pharma segment is expected to surpass plasma with rapid expansion.
Paysign Is A Leader In Fintech Healthcare Payments With Durable Profitable Growth
Neutral
Seeking Alpha
3 months ago
Paysign, Inc. (PAYS) Q3 2024 Earnings Call Transcript
Paysign, Inc. (NASDAQ:PAYS ) Q3 2024 Earnings Conference Call November 5, 2024 5:00 PM ET Company Participants Mark Newcomer - President and CEO Jeff Baker - CFO Matt Turner - President, Patient Affordability Conference Call Participants Pete Heckmann - D.A. Davidson Gary Prestopino - Barrington Research Jon Hickman - Ladenburg Thalmann Operator Good afternoon.
Paysign, Inc. (PAYS) Q3 2024 Earnings Call Transcript
Neutral
Business Wire
3 months ago
Paysign, Inc. Reports Third Quarter 2024 Financial Results
HENDERSON, Nev.--(BUSINESS WIRE)--Paysign, Inc. (NASDAQ: PAYS), a leading provider of prepaid card programs, comprehensive patient affordability offerings, digital banking services and integrated payment processing, today announced financial results for the third quarter 2024. “We are pleased to report strong third-quarter results, achieving 23.0% revenue growth and a 20.6% increase in adjusted EBITDA,” said Mark Newcomer, President & CEO of Paysign. “Revenue from patient affordability prog.
Paysign, Inc. Reports Third Quarter 2024 Financial Results
Neutral
Business Wire
4 months ago
Paysign to Host Third Quarter 2024 Earnings Call
HENDERSON, Nev.--(BUSINESS WIRE)--Paysign to Host Third Quarter 2024 Earnings Call.
Paysign to Host Third Quarter 2024 Earnings Call
Positive
Zacks Investment Research
4 months ago
Is Paysign (PAYS) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Is Paysign (PAYS) Stock Undervalued Right Now?
Positive
Zacks Investment Research
5 months ago
Is Paysign (PAYS) Stock Outpacing Its Business Services Peers This Year?
Here is how Paysign, Inc. (PAYS) and Recruit Holdings Co., Ltd. (RCRRF) have performed compared to their sector so far this year.
Is Paysign (PAYS) Stock Outpacing Its Business Services Peers This Year?
Positive
Zacks Investment Research
5 months ago
Is Paysign (PAYS) Outperforming Other Business Services Stocks This Year?
Here is how Paysign, Inc. (PAYS) and Recruit Holdings Co., Ltd. (RCRRF) have performed compared to their sector so far this year.
Is Paysign (PAYS) Outperforming Other Business Services Stocks This Year?
Positive
Seeking Alpha
6 months ago
Paysign: The Return Of The King Of Medical Fintech
Niche Focus: Paysign specializes in healthcare payment solutions, primarily in plasma donor compensation and patient affordability programs. Revenue Growth: Significant growth in the patient affordability segment is now a substantial part of total revenue. Financial Resilience: The company has shown strong revenue and margin recovery post-pandemic, with promising future growth.
Paysign: The Return Of The King Of Medical Fintech
Charts implemented using Lightweight Charts™